NCT04966949

Brief Summary

To compare the perioperative, functional, and oncologic outcomes between nerve sparing and lateral prostate capsule sparing robot-assisted radical cystectomy with orthotopic ileal neobladder in male patients with bladder cancer.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Sep 2021

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 9, 2021

Completed
10 days until next milestone

First Posted

Study publicly available on registry

July 19, 2021

Completed
1 month until next milestone

Study Start

First participant enrolled

September 1, 2021

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 31, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 31, 2023

Completed
Last Updated

July 19, 2021

Status Verified

July 1, 2021

Enrollment Period

2 years

First QC Date

July 9, 2021

Last Update Submit

July 15, 2021

Conditions

Outcome Measures

Primary Outcomes (3)

  • day-time continence rate

    Patients were considered continent when they required 0 or 1 safety pad during the day time

    6 months

  • night-time continence rate

    Patients were considered continent when they required 0 or 1 safety pad during the night.

    6 months

  • postoperative sexual function

    The sexual function are evaluated by the international index of erectile function-5 (IIEF-5).

    6 months

Secondary Outcomes (5)

  • perioperative complication rate

    3 months

  • operative time

    24 hours

  • estimated blood loss

    24 hours

  • overall survival

    1 year

  • recurrence-free survival

    1 year

Study Arms (2)

lateral prostate capsule sparing group

EXPERIMENTAL

Patients will be preverved the lateral prostate capsule during the resection of bladder and prostate of the operation.

Procedure: lateral prostate capsule sparing or neurovascular bundles sparing

nerve sparing group

ACTIVE COMPARATOR

Patients will be preverved the neurovascular bundles during the resection of bladder and prostate of the operation.

Procedure: lateral prostate capsule sparing or neurovascular bundles sparing

Interventions

When resect the bladder and prostate, the lateral prostate capsule or neurovascular bundles will be preserved.

lateral prostate capsule sparing groupnerve sparing group

Eligibility Criteria

Age18 Years+
Sexmale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Male patients aged 18 or older.
  • Patients those who are diagnosed with urothelial carcinoma.
  • Patients those who are without tumour in the bladder neck or urethra, and prostate cancer was ruled out by MRI and serum T-PSA\<2.5ng/ml.
  • Patients those who are capable of receiving radical cystectomy with orthotopic ileal neobladder.
  • Patients those who are able to cooperate and complete the follow-up.
  • Patients those who volunteer to participate in this study and sign the informed consens.

You may not qualify if:

  • Patients thsoe who are diagnosed distant metastasis before surgery.
  • Patients those who are diagnosed with other malignancies.
  • Patients those who had received pelvic radiotherapy or major pelvic operation.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sun Yat-sen Memorial Hospital, Sun Yat-sen University

Guangzhou, Guangdong, 510120, China

Location

MeSH Terms

Conditions

Urinary Bladder Neoplasms

Condition Hierarchy (Ancestors)

Urologic NeoplasmsUrogenital NeoplasmsNeoplasms by SiteNeoplasmsFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesUrinary Bladder DiseasesUrologic DiseasesMale Urogenital Diseases

Study Officials

  • Jian Huang, MD

    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 9, 2021

First Posted

July 19, 2021

Study Start

September 1, 2021

Primary Completion

August 31, 2023

Study Completion

August 31, 2023

Last Updated

July 19, 2021

Record last verified: 2021-07

Data Sharing

IPD Sharing
Will not share

Locations